A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children With Pulmonary Arterial Hypertension
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms TOMORROW
- Sponsors Actelion Pharmaceuticals
- 02 Oct 2017 Planned initiation date changed from 12 Sep 2017 to 5 Nov 2017.
- 31 Aug 2017 Planned initiation date changed from 24 Aug 2017 to 12 Sep 2017.
- 31 Aug 2017 Status changed from not yet recruiting to recruiting.